FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-cabozantinib-pancreatic-neuroendocrine-tumors-2025a10007bi?src=rss